Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance

Clinical Therapeutics

Volumn 22, Issue 1, 2000, Pages 2-14

  Gotfried, Mark H ^a  

^a NONE   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Antimicrobial resistance; Clarithromycin; Macrolide; Streptococcus pneumoniae

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG EFFICACY; ERADICATION THERAPY; HEALTH SURVEY; HOST RESISTANCE; HUMAN; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033968105     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87973-4     Document Type: Article

References (37)

1. 1. Bartlett JG, Mundy LM. Community-ac-quired pneumonia. N Engl J Med. 1995; 333:1618-1624.
2. 2. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell G, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; 1995: 608-612.
3. 3. Lark RL, Chenoweth C. Antimicrobial resistance in community-acquired respiratory tract pathogens. Compr Ther. 1999; 25:20-29.
4. 4. DeAbate CA, Myers D, Henry D, et al. Efficacy and tolerability of once-daily grepafloxacin compared to clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Drug Invest. 1999;17:21-31.
5. 5. Anzueto A, Niederman MS, Tillotson GS, et al. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID versus clarithromycin 500 mg BID. Clin Ther. 1998;20:1-16.
6. 6. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults. Ann Intern Med. 1988;108:616-625.
7. 7. Ruiz-Gonzalez A, Falguera M, Nogues A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologie study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385-390.
8. 8. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA. 1995;273: 957-960.
9. 9. DeBock GH, Dekker FW, Stolk J, et al. Antimicrobial treatment in acute maxillary sinusitis: A meta-analysis. J Clin Epidemiol. 1997;50:881-890.
10. 10. Ziering W, McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection. 1998;26:72-75.
11. 11. Doern GV. Mechanisms and current rates of resistance. Am J Managed Care. 1998; 4(Suppl):S531-S537.
12. 12. Bachand JRT. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A):91-100.
13. 13. Aldons PM. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A):101-108.
14. 14. Poirer R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1991;27(Suppl A): 109-116.
15. 15. Guay DRP, Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis. J Intern Med. 1992;23:295-301.
16. 16. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis. 1992;15:77-83.
17. 17. Kislak JW, Razavi LMB, Daly AK, et al. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci. 1965;250:261-268.
18. 18. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilits influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075-2080.
19. 19. Spika JS, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 1991;163:1273-1278.
20. 20. Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother. 1994;38: 2419-2425.
21. 21. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three third-generation cephalosporins against U.S. isolates of Streptococcus pneumoniae: A 1995 surveillance study. Diagn Microbiol Infect Dis. 1996;25:89-95.
22. 22. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
23. 23. Jones RN, Ballow CH, Schentag JJ, et al. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis. 1998;31:313-325.
24. 24. Thornsberry C, Ogilvie P, Kahn J, and the Laboratory Investigator Group. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis. 1997; 29:249-257.
25. 25. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764-770.
26. 26. Thornsberrry C, Brown SD, Yee C, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Infect Med. 1993;93(Suppl):15-24.
27. 27. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. 1998;27:730-738.
28. 28. Trovan® approval package, NDA 20-759 and 20-760. Rockville, Md: Center for Drug Evaluation and Research; December 1997. Application 020759020760.
29. 29. Gerardo SH, Citron DM, Claros MC, et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother. 1996;40:2413-2415.
30. 30. Goldstein EJC, Citron DM, Merriam CV. Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother. 1999:43:705-707.
31. 31. Retsema JA, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis. 1991;10:834-842.
32. 32. Shortridge D, Ramer N, McDaniel D, et al. Streptococcus pneumoniae susceptibility testing with clarithromycin: Comparison of reference broth microdilution method to Etest. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif.
33. 33. Tramont EC, Hoover DL. General or non-specific host defense mechanisms. In: Mandell G, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone; 1995: 30-35.
34. 34. Gotfried MH, Neuhauser MM, Garey KW, et al. In vitro Streptococcus pneumoniae (SP) resistance: Correlation with outcomes in patients with respiratory infections. J Antimicrob Chemother. 1999;44(Suppl A):83.
35. 35. Conte JE, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother. 1995;39:334-338.
36. 36. Conte JE, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother. 1996;40:1617-1622.
37. 37. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 1997;41:1399-1402.